However, over the six year period, it was shown that only phospho-tau217 (abbreviated to p-tau217) was related to Alzheimer’s disease pathology, a decline in cognitive performance and increased brain atrophy typical of incipient Alzheimer’s.
Scientists concluded that p-tau217 will be an “ideal” for the detection of relevant disease-modifying effects of novel interventions.
First study author, Doctor Nicholas Ashton from the University of Gothenburg, said: “Distinctive blood tests may be optimal for the identification of Alzheimer’s pathology or for monitoring of disease progression and therefore have different roles in clinical trials.
“This study has shown that p-tau217 is uniquely placed to be an optimal test for monitoring patients in both a clinical setting and a trial setting because of its longitudinal association with Alzheimer’s development.”
READ MORE: How to tell you’ve had a heart attack for a ‘few minutes’ without realising – the signs
